AstraZeneca's $1B Drug Protections Too Vague, Generics Say
Generic drugmakers urged the High Court to revoke patent protections for AstraZeneca's $1 billion Type-2 diabetes treatment Forxiga at the start of invalidity proceedings on Monday as the pharmaceutical companies hope...To view the full article, register now.
Already a subscriber? Click here to view full article